The first was a one-time stock option exchange program for non-Executive Committee employees, which received significant support from stockholders. The second proposal allowed for the adjournment of ...

Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a "right to win" on the obesity drugs that have become a major ...

Local health officials are hosting free flu vaccine clinics throughout November across eastern Idaho. The clinics by Eastern ...

The U.S. Food and Drug Administration is yet to authorize the two modified boosters, for which applications were submitted ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech ...

Read more from STAT’s Chelsea Cirruzzo and Daniel Payne for more details on what Vance had to say and what attendees received ...

The S&P 500 Healthcare sector (XLV) experienced a slight rise in average short interest during October, moving from 1.91% to ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...

Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 ...